Weekly update Companies AI-cruiter Recruiting

BridGene Biosciences

Founded: 2018

Location: San Jose, CA

Employee range: 11 - 50

Clinical stage: RD

Therapy area: Oncology

Drug types: ONC

Lead product: Undisclosed

Product link: https://www.bridgenebio.com/home#Pipline

Funding: $38.5M B Jul 2022; $12M A May 2021

Investors: Lapam Capital, Junson Capital, Dyee Capital

bridgenebio.com

linkedin.com

job board

Short description:

Small molecules that drug traditionally undruggable targets

Drug notes:

3 additional undisclosed programs RD oncology

Long description:

BridGene Biosciences is developing small molecules intended to target previously undruggable targets. Currently, about 90% of disease-associated diseases cannot be targeted by traditional therapies as addressable binding sites are unknown. BridGene is using their chemoproteomics platform, IMTACTM, to screen small molecules against all proteins in live cells to discover drug candidates for high value and hard-to-drug targets. The IMTACTM platform uses covalent chemistry, chemical proteomics and quantitative mass spectrometry to screen cells in different cellular states and different cell compartments to greatly increase the application scope of BridGene’s chemoproteomic technology. Using their platform, BridGene is advancing a deep and diversified pipeline focusing on new oncology drugs.

Jobs:

Main

Contact: recruit@workinbiotech.com